Internal Medicine Alert
RSSArticles
-
Mother Was Right: You Are What You Eat
In a study of simplified enterotypes as prognostic markers for successful body fat loss on two different diets, participants with a greater ratio of Prevotella to Bacteroides appeared more susceptible to lose body fat on diets high in fiber and whole grains.
-
Diet High in Carbohydrates, Not Fats, Drives Mortality
A prospective epidemiological cohort study of people 35-70 years of age in 18 countries showed that a higher intake of carbohydrates increased total mortality, while the intake of fats of all kinds did not. A higher intake of saturated fat reduced stroke mortality.
-
Aberrant Conduction or Ventricular Bigeminy?
How would you interpret the tracing? Are these multifocal (multiform) premature ventricular contractions?
-
Clinical Briefs
In this section: managing diabetes; elective surgery; and nephrolithiasis patients.
-
Tisagenlecleucel Suspension (Kymriah)
Kymriah is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.
-
What Is the Ideal Target for Blood Pressure Control?
Researchers organized a study to address quality-of-life outcomes based on recent blood pressure recommendations.
-
Do Antibiotics Reduce Hormonal Contraceptive Effectiveness?
Researchers conducted a systematic review of studies that evaluated the effect of concomitant non-rifamycin antibiotic use on hormonal contraceptive effectiveness. Although data are limited, there was no evidence to support the existence of drug interactions.
-
Screening for Prostate Cancer May Offer Survival Benefits
Using a mathematical model to account for differences in implementation and baseline screening, researchers reassessed mortality data from two major studies and discovered that screening led to a 25-30% reduction of prostate cancer death in both.
-
Clinical Briefs
In this section: diagnosing pulmonary embolism; tackling early prostate cancer; and treating urinary tract symptoms.
-
Glecaprevir and Pibrentasvir Tablets (Mavyret)
The FDA has approved a dual fixed-dose combination of glecaprevir, a NS3/4A protease inhibitor, and pibrentasvir, a NS5A inhibitor, for the treatment of all major genotypes (1-6) of chronic hepatitis C infections.